InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,853.75
(
-0.06%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

kipster210

Send PM Follow Ignore
Followers 1
Posts 162
Boards Moderated 0
Alias Born 05/30/2009

kipster210

Re: iandy post# 17180

Friday, 03/16/2012 9:18:08 AM

Friday, March 16, 2012 9:18:08 AM

Post# of 80490
FDA says Merck's ridaforolimus meets study goal




WASHINGTON, March 16 | Fri Mar 16, 2012 8:51am EDT
(Reuters) - U.S. health regulators on Friday said Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic bone sarcoma.

A review document released by the Food and Drug Administration also said the treatment known by the brand name Taltorvic showed no new or unexpected safety signals in clinical research.

STOCKSREGULATORY NEWSMARKETSHEALTHCARE
Related Quotes and News
COMPANYPRICERELATED NEWS
Merck & Co Inc
MRK.N
$38.06
-0.16-0.42%
FDA says Merck's ridaforolimus meets study goal
FDA says Merck's ridaforolimus meets study goal
More MRK.N News »
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up